Navigation Links
Researchers chart the genetic mechanisms behind the genesis of fat cells
Date:11/6/2007

SINGAPORE -- Obesity is a well known risk factor for prostate, breast and colon cancer, but recent studies have shown that a protein responsible for generating fat cells also plays an important role in cancer. Researchers at the Genome Institute of Singapore have conducted, for the first time, a genome-wide analysis of how the protein, called perixosome proliferator-activated receptor gamma (PPARg), turns on various genes related to obesity.

Simply suppressing the protein entirely could prevent the generation of adipocytes the precursors to fat cells the researchers say, but it would decrease the proteins beneficial properties. Instead, the researchers believe that by identifying the gene targets of PPARg, they could open up new targets for drug development against a number of diseases, including obesity, diabetes and cancer. They present their findings today at the AACR Centennial Conference on Translational Cancer Medicine.

To date, only a limited number of direct targets for PPARg have been identified. Our findings provide a genome-wide map of PPARg binding sites during the course of adipocyte differentiation, said M. Sabry Hamza, Ph.D, a postdoctoral research fellow at the Genome Institute of Singapore, a division of Singapores Agency for Science, Technology and Research (A*STAR). These results together with the expression profile of genes that are dependent of PPARg expression provide us with clues into the transcriptional circuitry during adipogenesis, the process by which adipocytes differentiate into different types of fat tissue.

With funding from A*STAR, we have identified direct targets of PPARg, that when inhibited lead to a dramatic reduction of adipogenic potential, Hamza said. Ongoing analysis will help us decipher whether these direct targets control adipogenesis, insulin sensitization or determination of fat cell type.

According to Hamza, PPARg inhibits the proliferation and lowers the threshold for apoptosis -- the process by which cancer cells destroy themselves. In addition, significant increase in tumor suppressor BRCA1 is induced when breast cancer cells are exposed to PPARg agonists, said Hamza. Although indirect, the role of PPARg as it relates to obesity and cancer is intriguing.

So far, Hamza and his colleagues have identified a number of new PPARg target genes which are connected to adipogenesis and insulin sensitivity. Currently available marketed oral hypoglycemic drugs, although very potent in treating type II diabetes, cause detrimental sides effects including weight gain, liver toxicity and heart disease, says Hamza. Using drugs which target specifically those PPARg targets regulating insulin sensitivity could hence present a safer and more efficient therapeutical approach, said Hamza.

According to Hamza, the researchers next step will be to apply their data to mouse models in order to compare PPARg activity in fat tissue of mice under high-fat and normal conditions and to further characterize the regulation of PPARg target genes identified in this study.


'/>"/>
Contact: Staci Vernick Goldberg
staci.goldberg@aacr.org
267-646-0616
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... September 26, 2017 , ... Atmosera ... Release Management as a Service (RMaaS) to automate the deployment of ... include any companies, e-tailers, and web development agencies who want to improve time-to-revenue ...
(Date:9/26/2017)... ... September 26, 2017 , ... Two ... only entirely new and different, it is scientifically proven as well: ABAlife™. Euromed ... has received an exclusive license agreement with BioTherapeutics Inc. for patented technology for ...
(Date:9/26/2017)... ... 26, 2017 , ... After a summer-long contest to crown ... Designated Drivers proudly announced the winners of the HEROtini Mocktail Challenge at the ... on the challenge of competing in three categories: Best HEROtini Mocktail, Top HEROtini ...
(Date:9/26/2017)... Falls Church, VA (PRWEB) , ... September 26, 2017 , ... ... FDAnews and Cerulean Associates LLC **, Dec. 5-6, 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity ... its investigators: “If initial findings indicate the firm’s electronic records may not be trustworthy ...
(Date:9/26/2017)... Scotch Plains, NJ (PRWEB) , ... September 26, ... ... Surgery Fellowship trained orthopedic surgeon and the Chair of the Leg, Ankle, and ... Dr. Kovatis is currently the only fellowship trained orthopedic surgeon at Hackensack UMC ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
Breaking Medicine Technology: